Search

Your search keyword '"Quirt, Ian"' showing total 48 results
Start Over Author "Quirt, Ian"
48 results on '"Quirt, Ian"'

4. Lecture Handouts of Projected Slides in a Medical Course.

Author

Amato, Dominick and Quirt, Ian

Abstract

In a third-year medical school hematology course, handouts reproducing all or most of the 35mm slides used during the lecture are given at the beginning of class. The slides are reproduced on the left, with room for note-taking on the right. Despite some disadvantages, the method is seen as helpful. (Author/MSE)

Published
1991

5. Improved survival with ipilimumab in patients with metastatic melanoma

Author

Hodi, F. Stephen, OEDay, Steven J., McDermott, David F., Weber, Robert W., Sosman, Jeffrey A., Haanen, John B., Gonzalez, Rene, Robert, Caroline, Schadendorf, Dirk, Hassel, Jessica C., Akerley, Wallace, van den Eertwegh, Alfons J.M., Lutzky, Jose, Lorigan, Paul, Vaubel, Julia M., Linette, Gerald P., Hogg. David, Ottensmeier, Christian H., Lebbe, Celeste, Peschel, Christian, Quirt, Ian, Clark, Joseph I., Wolchok, Jedd D., Weber, Jeffrey S., Tian, Jason, Yellin, Michael J., Nichol, Geoffrey M., Hoos, Axel, and Urba, Walter J.

Subjects
Melanoma -- Drug therapy, Monoclonal antibodies -- Usage, Monoclonal antibodies -- Health aspects, T cells -- Research
Abstract

A study was conducted to evaluate the efficacy and safety of ipilimumab as a form of treatment and survival in the case of patients with metastatic melanoma. Results indicated that ipilimumab improved the overall survival rate in the case of such patients.

Published
2010

6. Pyruvate kinase deficiency and malaria

Author

Ayi, Kodjo, Min-Oo, Gundula, Serghides, Lena, Corckett, Maryanne, Kirby-Allen, Melanie, Quirt, Ian, Gros, Philippe, and Kain, Kevin C.

Subjects
Malaria -- Causes of, Malaria -- Care and treatment, Plasmodium falciparum -- Health aspects, Pyruvate kinase -- Genetic aspects, Pyruvate kinase -- Health aspects
Abstract

The deficiency of pyruvate kinase in humans is believed to provide protection against malaria caused by plasmodium falciparum in areas where the disease is endemic.

Published
2008

10. Learning fiberoptic intubation on a simple model transfers to the O.R.

Author

Naik, Viren, Matsumoto, Edward, Houston, Patricia, Hamstra, Stanley, Yeung, Raymond, Mallon, Joseph, Martire, Terry, Zwack, Rhonda M., Campbell, David C., Breen, Terrance W., Yip, Ray W., Roy, Jean-Denis, Girard, Michel, Drolet, Pierre, Guay, Joanne, Bolis, Rafik S., LeDez, Kenneth, Balatbat, J. T., Mukherji, J., Ali, M. J., Carroll, J., Karski, J. M., Sui, S., Cheng, D. C. H., Banner, Robert, Yip, Raymond, Zondervan, James, Chow, Vance, McMillan, Dean, Fisher, Judy, Lattermann, Ralph, Carli, Franco, Wykes, Linda, Schricker, Thomas, Mazza, Louise, Carli, Franco, Danjoux, Gerard, Thomas, David, Lennox, Pamela H., Henderson, Cynthia, Martin, Lynn, Mitchell, G W E, Vaghadia, Himat, Jassal, Rajive, Thomson, Ian R., Hudson, Robert J., McGuire, Glenn, Manninen, Pirjo, El-Beheiry, Hossam, Lozano, Andres, Wennberg, Richard, Archer, David P., Tang, Tim K. K., Staveley, Ian R., Goldstein, David H., VanDenKerkhof, Elizabeth G., Hall, Richard I., Rocker, Graeme M., O’Connor, J. P., Dunham, Jacquelyn I., Mikelberg, Frederick S., Dulovic, Gordana, Jenkins, Kathryn L., Correa, Robin, Wong, David T., McGuire, Glenn P., Fayad, A. A., Paul, J., Yang, H., Sawchuk, C., Brown, Karen A., Bates, Jason H. T., Edington, Robert, Pridham, Jeremy, Mukherji, Jayanta, Karski, Jacek M., Balatbat, Joselito, Carroll, Jo, Chun, Rosa, Cheng, Davy CH, Karski, J., DeBrouwere, R., Mathieu, M., Carroll, J., Feindel, C., Cheng, D., Clairoux, Michel, Coutu, Stéphane, McCluskey, Stuart A., Karkouti, Keyvan, Ghannam, Mohammed, Jewett, Michael, Rampersaud, Raja, Yau, Terry, Quirt, Ian, Carver, Edmund D., Kim, P., Crawford, Mark W., Finley, G. Allen, Breau, Lynn M., McGrath, Patrick J., Camfield, Carol, Mak, Peter H. K., Hui, Theresa W. C., Irwin, Michael G., Carli, Franco, Trudel, Judith, Belliveau, Paul, Mayo, Nancy, Clunie, Michelle L., Crone, Lesley-Ann L., Klassen, Linda J., Yip, Raymond W., Hubert, Bernard, Radomski, Marek, Blaise, Gilbert, Renzi, Paolo M., Paradis, Marie-Claude, Martin, René, Parent, Michel, Parent, Pierre, Gagnon, Daniel, Tétrault, Jean-Pierre, Prabhu, Atul J., Philip, Beverly K., Higgins, Patrick P., Blanshard, Hannah J., van Rensselaer, Stéphanie, Chung, Frances F., Caraiscos, Valerie B., MacDonald, John F., Orser, Beverley A., Schreiber, Markus, Georgieff, Michael, Jin, Fengling, Chung, Frances, Tong, Doris, Reiz, Joseph L., Harsanyi, Zoltan, Miceli, Paula C., Darke, Andrew C., Roy, Jean-Sébastien, St-Pierre, Jacques, Norman, Peter H., Daley, M. Denise, Turner, Kim E., Parlow, Joel L., Tod, Deborah A., Avery, Nicole D., Nicole, Pierre C., Trépanier, Claude A., Lessard, Martin R., Marcoux, Sylvie, Cowie, Dean A., Gelb, Adrian W., Shoemaker, J. Kevin, Baskett, Roger, Lim, Ben C., Dangor, Ayoub, Morgan, Pamela J., Cleave-Hogg, Doreen, Doyle, D. John, Byrick, Robert, Filipovi, Dusanka, Cashin, Fred, Chiu, Michelle, Kemp, Toby J., Bryson, Gregory L., Cleland, Mark J., Crosby, Edward T., Harioka, Tokuya, Nomura, Koichiro, Ando, Norioki, Ikegami, Naoyuki, Aoki, Toshiki, Maltby, J. Roger, Beriault, Michael T., Watson, Neil C., Liepert, David J., Fick, Gordon H., Maltby, J. Roger, Liepert, David, Prabhu, Atul J., Correa, Robin K., Wong, David T., Chung, Frances, Goyagi, Tom, Bhardwaj, Anish, Hum, Patricia D., Traystman, Richard D., Kirsch, Jeffrey R., Bainbridge, Daniel T., Swaminathan, Madhav, McCreath, Brian J., Djaiani, George, Grocott, Hilary P., Day, Fergal, Karski, Jacek, Djaiani, George, Tan, Jens, Cheng, Davy, Wake, Pamela J., Ali, Mohamed, Karski, Jacek, Sui, Sam, Guenther, Craig, Mullen, John, Bentley, Michael, Koshal, Arvind, Finegan, Barry, Murtha, William, Fredrickson, Michael J., Luginbuehl, Igor A., Bissonnette, Bruno, Granton, Jeff T., Platt, Hugh, and Craen, R. A.

Published
2001
Full Text
View/download PDF

16. Escalated as compared with standard doses of doxorubicin in BACOP therapy for patients with non-Hodgkin's lymphoma

Author

Meyer, Ralph M., Quirt, Ian C., Skillings, Jamey R., Cripps, M.C., Bramwell, Vivien H.C., Weinerman, Brian H., Gospodarowicz, Mary K., Burns, Bruce F., Sargeant, Ann Marie, Shepherd, Lois E., Zee, Benny, and Hryniuk, William M.

Subjects
Non-Hodgkin's lymphomas, Doxorubicin -- Dosage and administration, Chemotherapy -- Evaluation
Abstract

Increased doses of doxorubicin may not improve the survival of non-Hodgkin's lymphoma patients. Non-Hodgkin's lymphoma is a cancer of the lymph tissue accompanied by lymph node enlargement. Of 238 patients with non-Hodgkin's lymphoma, 119 were assigned to receive increased doses of doxorubicin and 119 were assigned to receive standard doses. Because of severe white blood cell depletion, only 56 patients received escalated doses. The two groups did not differ in their response to treatment. The overall response rate was 88% in the escalated therapy group and 84% in the standard therapy group. Forty-eight percent of those in the escalated therapy group survived five years, compared to 60% in the standard therapy group. The five-year survival rates without disease progression were 51% in the escalated therapy group and 53% in the standard therapy group. More deaths in the escalated therapygroup were a result of treatment complications or drug toxicity than in the standard therapy group.

Published
1993

21. Melanoma Early Detection and Awareness

Author

Wainstein, Alberto, primary, Algarra, Salvador Martin, additional, Bastholt, Lars, additional, Cinat, Gabriela, additional, Demidov, Lev, additional, Grob, Jean Jacques, additional, Guo, Jun, additional, Hersey, Peter, additional, Espinosa, Enrique, additional, Schachter, Jacob, additional, Whitaker, Dagmar, additional, Quirt, Ian, additional, Hauschild, Axel, additional, and Rutkowski, Piotr, additional

Published
2015
Full Text
View/download PDF

24. Expansion and Characterization of Human Melanoma Tumor-Infiltrating Lymphocytes (TILs)

Author

Nguyen, Linh T., primary, Yen, Pei Hua, additional, Nie, Jessica, additional, Liadis, Nicole, additional, Ghazarian, Danny, additional, Al-Habeeb, Ayman, additional, Easson, Alexandra, additional, Leong, Wey, additional, Lipa, Joan, additional, McCready, David, additional, Reedijk, Michael, additional, Hogg, David, additional, Joshua, Anthony M., additional, Quirt, Ian, additional, Messner, Hans, additional, Shaw, Patricia, additional, Crump, Michael, additional, Sharon, Eran, additional, and Ohashi, Pamela S., additional

Published
2010
Full Text
View/download PDF

26. Predictors of Mortality in Patients Undergoing Autologous Stem Cell Transplant (ASCT) Admitted to the Intensive Care Unit: An Institutional Review of 1013 Transplant Patients over Five Years.

Author

Trinkaus, Martina A., primary, Lapinsky, Stephen E., additional, Hallett, David C., additional, Franke, Norman, additional, Winter, Andrew, additional, Crump, Michael, additional, Reece, Donna E., additional, Chen, Christine, additional, Trudel, Suzanne, additional, Quirt, Ian, additional, Keating, Armand, additional, and Mikhael, Joseph R., additional

Published
2007
Full Text
View/download PDF

29. Patients Previously Transfused or Treated with Epoetin Alfa at Low Baseline Hemoglobin Are at Higher Risk for Subsequent Transfusion: An Integrated Analysis of the Canadian Experience

Author

Quirt, Ian, primary, Kovacs, Michael, additional, Couture, Félix, additional, Turner, A. Robert, additional, Noble, Michael, additional, Burkes, Ronald, additional, Dolan, Sean, additional, Plante, Richard K., additional, Lau, Catherine Y., additional, Chang, José, additional, and Camacho, Fernando, additional

Published
2006
Full Text
View/download PDF

32. Treatment of Advanced Hodgkin's Disease With Chemotherapy—Comparison of MOPP/ABV Hybrid Regimen With Alternating Courses of MOPP and ABVD

Author

Connors, Joseph M., primary, Klimo, Paul, additional, Adams, Grenfell, additional, Burns, Bruce F., additional, Cooper, Ian, additional, Meyer, Ralph M., additional, O'Reilly, Susan E., additional, Pater, Joseph, additional, Quirt, Ian, additional, Sadura, Anna, additional, Shustik, Chaim, additional, Skillings, Jamey, additional, Sutcliffe, Simon, additional, Verma, Shailendra, additional, Yoshida, Sam, additional, and Zee, Benny, additional

Published
1997
Full Text
View/download PDF

37. Neurologic disorders in patients with small cell lung cancer.

Author

Sculier, Jean-Paul, Feld, Ronald, Evans, William K., Deboer, Gerrit, Shepherd, Frances A., Payne, David G., Pringle, Jack F., Yeoh, Joo-Lim, Quirt, Ian C., Curtis, John E., Myers, Robert, Herman, James G., Sculier, J P, Feld, R, Evans, W K, DeBoer, G, Shepherd, F A, Payne, D G, Pringle, J F, and Yeoh, J L

Published
1987
Full Text
View/download PDF

38. Superior vena caval obstruction syndrome in small cell lung cancer.

Author

Sculier, Jean Paul, Evans, William K., Feld, Ronald, Deboer, Gerrit, Payne, David G., Shepherd, Frances A., Pringle, John F., Yeoh, J. Lim, Quirt, Ian C., Curtis, John E., Herman, James G., Sculier, J P, Evans, W K, Feld, R, DeBoer, G, Payne, D G, Shepherd, F A, Pringle, J F, Yeoh, J L, and Quirt, I C

Published
1986
Full Text
View/download PDF

40. Epoetin alfa in patients not on chemotherapy – Canadian data

Author

Quirt, Ian, Robeson, Christine, Lau, Cathy Y., Kovacs, Michael, Burdette-Radoux, Susan, Dolan, Sean, Tang, Shou-Ching, McKenzie, Michael, and Couture, Felix

Abstract

A prospective open-label study was designed to evaluate the safety, efficacy, and impact on quality of life of recombinant human erythropoietin (rHuEPO, epoetin alfa) therapy for cancer-related anemia. Of the 401 patients enrolled at 34 centers from across Canada, a cohort of 183 patients did not receive chemotherapy during the 16-week study period. All patients received epoetin alfa 150 IU/kg subcutaneously 3 times per week. The dose was increased to 300 IU/kg if the hemoglobin level did not increase by at least 1.0 g/dL after 4 weeks. Epoetin alfa therapy significantly increased hemoglobin levels and reduced transfusion requirements. Moreover, epoetin alfa provided statistically significant and clinically meaningful improvements in quality of life as measured by the Functional Assessment of Cancer Therapy–Anemia and Linear Analog Scale Assessment (also known as Cancer Linear Analog Scale). Increases in hemoglobin were correlated significantly with improvements in quality of life as well as Eastern Cooperative Oncology Group performance status. Treatment with epoetin alfa was well tolerated. These results demonstrate that epoetin alfa therapy is effective and safe in cancer patients with anemia, regardless of whether they are or are not receiving chemotherapy. Semin Oncol 29 (suppl 8):75-80. Copyright 2002, Elsevier Science (USA). All rights reserved.

Published
2002
Full Text
View/download PDF

41. Combined Modality Treatment of Small Cell Carcinoma of the Lung

Author

Feld, Ronald, Pringle, John F., Evans, William K., Keen, Colin W., Quirt, Ian C., Curtis, John E., Baker, Michael A., Yeoh, J. L., Deboer, Gerrit, and Brown, Thomas C.

Abstract

• Ninety patients with extensive and 61 with limited small cell carcinoma of the lung were treated with three courses of intravenous chemotherapy (cyclophosphamide, doxorubicin hydrochloride, and vincristine sulfate) followed by radiotherapy to intrathoracic disease, and a second three-drug oral combination consisting of lomustine, procarbazine, and methotrexate for one year. Among the 147 patients who were evaluated, 55 of 66 (83%) with limited disease and 53 of 81 (65%) with extensive disease showed response after three courses of chemotherapy. The complete response rate in patients with limited disease prior to radiotherapy was 24%, but increased to 58% when evaluated following radiotherapy. The median survival was 47 weeks for patients with limited disease and 36 weeks for those with extensive disease. A 24% two-year survival is projected for complete responders. Important prognostic factors for survival are performance status, extent of disease, and sex, with female subjects doing somewhat better than male subjects. Among patients with limited disease, 45% failed within the CNS despite the use of chemotherapeutic agents that cross the blood-brain barrier. The initial induction regimen and radiotherapy were well tolerated; the oral three-drug combination was more toxic and did not prevent CNS metastases.(Arch Intern Med 1981;141:469-473)

Published
1981
Full Text
View/download PDF

42. Sentinel lymph-node biopsy after previous wide local excision for melanoma.

Author

McCready, David R., Ghazarian, Danny M., Hershkop, Marlon S., Walker, Janet A., Ambus, Ulo, and Quirt, Ian C.

Subjects
LYMPH nodes, MELANOMA, DERMATOLOGIC surgery, METASTASIS, BIOPSY
Abstract

Focuses on sentinel lymph-node biopsy after previous wide local excision for melanoma. Use of a positive cohort study; Outcome measures; Accuracy of the biopsy; False-negative rates in this setting; Identification of clinically occult nodal metastases.

Published
2001

43. Superior vena caval obstruction syndrome in small cell lung cancer

Author

Sculier, Jean-Paul, Curtis, John J.E., Herman, James G, Evans, William W.K., Feld, Ronald, Deboer, Gerrit, Payne, David, Shepherd, Frances, Pringle, John J.F., Yeoh, Joey Lim, Quirt, Ian I.C., Sculier, Jean-Paul, Curtis, John J.E., Herman, James G, Evans, William W.K., Feld, Ronald, Deboer, Gerrit, Payne, David, Shepherd, Frances, Pringle, John J.F., Yeoh, Joey Lim, and Quirt, Ian I.C.

Abstract

In a series of 643 patients with small cell lung cancer (SCLC), 55 patients (8.6%) had signs or symptoms of superior vena caval obstruction syndrome (SVCO). Relatively long intervals from the onset of the first symptoms of SVCO to the start of therapy were observed, and invasive diagnostic procedures were safely performed in most patients. The pretreatment characteristics of patients with SVCO were not significantly different from those of patients without signs of the syndrome, and survival was similar in both groups. Patients with SVCO were usually treated first with induction chemotherapy, and prompt resolution of signs and symptoms occurred in the majority. Radiation was effective in controlling SVCO at relapse or after failure of initial chemotherapy. It was concluded that SVCO in patients with SCLC should be treated initially with systemic chemotherapy, as for other presentations of this disease. The current data do not support the commonly held view that SVCO in SCLC should be approached as an oncologic emergency. Copyright © 1986 American Cancer Society, SCOPUS: ar.j, FLWIN, info:eu-repo/semantics/published

Published
1986

Catalog

Books, media, physical & digital resources
See catalog results